N/A
N=60
Nurse-led Medicines' Monitoring in Care Homes: a Process Evaluation
Dementia
Bottom Line
View on ClinicalTrials.gov: NCT03110471 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jun 2020
Primary outcome: Primary: Number of Participants With Adverse Drug Reactions (ADRs) Treated — 30 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- West Wales Adverse Drug Reaction (WWADR) Profile (Behavioral); usual care (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Swansea University
- Primary completion
- Mar 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Drug Reactions (ADRs) Treated |
30 | — |
| SECONDARY Time for ADRe Administration (Including Interruptions) in Minutes |
27.7 | — |
| SECONDARY Number of Problems Identified Per Resident |
17.5 | — |
| SECONDARY Number of Changes to Care by Nurses Identified Per Resident |
2.3 | — |
| SECONDARY Number of Pharmacist Recommendations for Prescription Review Per Resident |
3.8 | — |
| SECONDARY Number of Drug Interactions Per Resident |
6.1 | — |
Summary
Lay Summary:
The investigators have shown in randomised controlled trials and observation studies that structured nurse-led medicines' monitoring using the WWADR Profile benefits patients, for example, by reducing pain and sedation and identifying high risk cardiovascular conditions. The investigators now aim to understand what is needed to sustain implementation of the WWADR Profile in routine practice and explore future directions.
The participants of the investigators previous research, 5 newly recruited care homes, and stakeholders - care home managers, carers, healthcare professionals, and service users - will be asked to contribute interviews, observations and reflective diaries/ accounts. The investigators are interested in their experiences of medication use, medication management, adverse effects and barriers and facilitators of medicine monitoring, and how electronic devices can enhance nurse-led monitoring.
Eligibility Criteria
Care Homes.
Inclusion criteria
Providing residential or nursing care or both to >4 service users meeting inclusion criteria below.
Willing to use the WWADR monitoring Profile in routine practice
Exclusion criteria
<5 residents meet the inclusion criteria Unwilling or unable to volunteer to undertake nurse-led medicines' monitoring
Inclusion Criteria service users:
- Inclusion criteria:
- Resident at the care home and expected to continue to be for 1 year;
- Currently taking one of antipsychotics, anti-epileptics/ mood stabilisers, antidepres-sants, benzodiazepines, Z drugs;
- Diagnosis of dementia, or dementia related condition, recorded; permanent local authority funding for dementia care; permanent cognitive impairment, but no diagnosis in care home notes.
- Willing and able to give informed, signed consent themselves, or where capacity is lacking, a consultee who is willing to give advice
Exclusion Criteria
- • Not well enough to participate, as screened by their nurses;
- Aged <18;
- Receiving active palliative care.
Professionals
Inclusion criteria
- Involved in the provision of care for service users described above
- Willing to participate in the study
Exclusion criteria
- Not involved with service users in care homes
- Unwilling to consent to participation
Data sourced from ClinicalTrials.gov (NCT03110471). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.